Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rhythm Pharmaceuticals Inc (NQ: RYTM ) 51.01 -0.76 (-1.47%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Rhythm Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 8 9 Next > 7 Stocks That Will Drive the Weight Loss Drugs Market March 28, 2024 The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. Via MarketBeat Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist March 25, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces New Employment Inducement Grants March 11, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Analyst Expectations For Rhythm Pharmaceuticals's Future February 22, 2024 Via Benzinga Preview: Rhythm Pharmaceuticals's Earnings February 21, 2024 Via Benzinga Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) January 25, 2024 Via Benzinga The Analyst Verdict: Rhythm Pharmaceuticals In The Eyes Of 7 Experts January 04, 2024 Via Benzinga Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences March 06, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan February 22, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update February 22, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces New Employment Inducement Grants February 08, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Analyst Expectations for Rhythm Pharmaceuticals's Future December 07, 2023 Via Benzinga Earnings Scheduled For February 22, 2024 February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. Via Benzinga Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome February 07, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024 January 31, 2024 Company to participate in fireside chats at Guggenheim’s 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire 2 biotechs with promising weight-loss drugs coming January 16, 2024 Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. Via MarketBeat Rhythm Pharmaceuticals Announces New Employment Inducement Grants January 12, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640 January 04, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates January 04, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces New Employment Inducement Grants December 15, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023 December 13, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma's Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial December 06, 2023 During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and... Via Benzinga Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event December 06, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces New Employment Inducement Grants November 13, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update November 07, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide) November 02, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Earnings Scheduled For November 7, 2023 November 07, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. Via Benzinga Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 October 25, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders October 19, 2023 EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END Via FinancialNewsMedia Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023 October 17, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.